Table 1.
Baseline clinical characteristics and laboratorial data of patients
| Total n = 99 |
Aortic regurgitation | Aortic stenosis | P value | |
|---|---|---|---|---|
| n = 32 (32%) | n = 67 (68%) | |||
| Male sex | 58 (58.6%) | 24 (75.0%) | 34 (50.7%) | 0.022 |
| Age (years) | 63 (55–69) | 57 (45–65) | 65 (60–71) | 0.001 |
| VHD aetiology | < 0.001 | |||
| Degenerative | 45 (45.5%) | 8 (25.0%) | 37 (55.2%) | |
| Bicuspid aortic valve | 35 (35.4%) | 7 (21.9%) | 28 (41.8%) | |
| Rheumatic | 7 (7.1%) | 5 (15.6%) | 2 (3.0%) | |
| Aortic or annular dilation | 6 (6.1%) | 6 (18.8%) | 0 (0.0%) | |
| Others | 6 (6.1%) | 6 (18.8%) | 0 (0.0%) | |
| Hypertension | 70 (70.7%) | 25 (78.1%) | 45 (67.2%) | 0.262 |
| Diabetes mellitus | 21 (21.2%) | 3 (9.4%) | 18 (26.9%) | 0.046 |
| Obstructive coronary artery disease (> 50%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| ACE inhibitors/ARBs | 66 (66.7%) | 27 (84.4%) | 39 (58.2%) | 0.010 |
| Other vasodilators | 30 (30.3%) | 14 (43.8%) | 16 (23.9%) | 0.044 |
| Beta-blockers | 17 (17.2%) | 10 (31.3%) | 7 (10.4%) | 0.010 |
| Diuretics | 63 (63.6%) | 22 (68.8%) | 41 (61.2%) | 0.465 |
| Symptoms for intervention | 93 (94%) | 26 (81%) | 67 (100%) | 0.001 |
| Dyspnoea | 86 (86.9%) | 25 (78.1%) | 61 (91.0%) | 0.110 |
| Functional class (NYHA) | 0.242 | |||
| I | 13 (13.1%) | 7 (21.9%) | 6 (9.0%) | |
| II | 37 (37.4%) | 13 (40.6%) | 24 (35.8%) | |
| III | 44 (44.4%) | 11 (34.4%) | 33 (49.3%) | |
| IV | 5 (5.1%) | 1 (3.1%) | 4 (6.0%) | |
| Angina | 41 (41.4%) | 6 (18.8%) | 35 (52.2%) | 0.002 |
| Syncope | 19 (19.2%) | 5 (15.6%) | 14 (20.9%) | 0.533 |
| Euroscore II (%) | 1.12 (0.87–1.54) | 1.13 (0.76–1.35) | 1.12 (0.91–1.62) | 0.224 |
| STS mortality score (%) | 0.91 (0.66–1.25) | 0.69 (0.57–0.89) | 1.09 (0.74–1.35) | < 0.001 |
| Haematocrit (%) | 41 (39–44) | 40 (37–44) | 41 (39–44) | 0.328 |
| CrCl (CG) (mL/min) | 76 (61–92) | 82 (61–98) | 73 (61–88) | 0.255 |
Values are expressed as n (%) or median (p25–p75). Bold P values indicate statistical significance.
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CrCl, creatinine clearance; CG, Cockcroft–Gault; NYHA, New York Heart Association; STS, Society of Thoracic Surgeons; VHD, valvular heart diseases.